CKYN Complete GHK-Cu Protocol launch, JN GLP-1 malnutrition review, Pfizer CFO transition, Biogen completes $5.6B Apellis acquisition, BIO 2026 opens June 22.
Read digest →HLB RGN-259 SEER-3 miss, NervGen NVG-291 RESTORE Phase 3 mid-2026, EndoCyclic ENDO-205 IND endometriosis, Bachem CCO, CROI GLP-1 in HIV.
Read digest →Marea MAR002 anti-GHR Phase 1 at ENDO 2026, EMA synthetic peptide guideline effective, Pep2Tango PTT-A 19%, France Wegovy reimbursement, Sontha 60K GLP-1 data.
Read digest →AmbioPharm $120M SC peptide expansion, Barclays raises Hims to $39, Frontiers CPP diabetes delivery, PCAC/503B 11-12 days, AHA/ACC CKM guideline, Ohio + Hanmi.
Read digest →D&D + LG AI lifts D&D 17%, Bloomberg gold-rush, UCSD semaglutide aging slowdown, Azitra +87%, Annals 41% cancer cut, Alabama bans research peptides.
Read digest →MVB-101 PSMA × FRα prostate PDC launches with $27M, PNAS Nexus tirzepatide vs semaglutide real-world, JAMA viewpoint on online peptides, employer GLP-1 drop.
Read digest →ENDO 2026 day 3: Entera EB613 single-tablet matches Forteo; Rhythm setmelanotide across PWS, AHO, BBS; Crinetics atumelnant CAH; Neurocrine Crenessity year 2.
Read digest →ENDO 2026 day 2: Crinetics Palsonify 2-yr OLE confirms acromegaly control; GLP-1 secondary effects on activity, fractures, fertility; TransCon CNP year 2.
Read digest →ENDO 2026 opens with PTH peptide showdown (Ascendis 82% 5-yr, MBX canvuparatide, Entera EB613); Crinetics Palsonify 2-yr OLE Sunday; rusfertide EHA 2026.
Read digest →Camurus second CRL on Oclaiz, MBX canvuparatide Phase 2 + 1-yr data set up Q3 Phase 3, Parabilis breaks IPO record at $670M, AJMC quantifies GLP-1 indication creep.
Read digest →Novo Wegovy pill clears UK MHRA today, Novartis del-brax met FSHD biomarker primary, Wegovy pill launched UAE June 3, Moes Group enters GHK-Cu OEM.
Read digest →PDUFA day for Camurus Oclaiz octreotide depot, Wegovy pill hits 3M US scripts in 5 months, Lantheus PNT2003 stay expires, and the peptide-enforcement watch.
Read digest →Post-ADA: Pfizer's monthly berobenatide hits 15.9%, retatrutide's dysesthesia signal sharpens to 20.9% at 12 mg, analysts read Lilly dominant and Roche me-too.
Read digest →ADA closes: orforglipron beats oral semaglutide head-to-head, elecoglipron 10.5%, Roche enicepatide 22.5%, survodutide fat-loss detail, plus new SoC.
Read digest →ADA Day 3: REIMAGINE 1/2/3 publishes in Lancet, mazdutide beats semaglutide head-to-head, zenagamtide hits 14.6% in T2D, elecoglipron and MetaVia add detail.
Read digest →ADA Day 2: full retatrutide TRIUMPH-1 + TRIUMPH-4 data, Lancet publishes TRANSCEND-T2D-1, an arrhythmia signal, plus the ADA Obesity Standards of Care.
Read digest →ADA opens: Structure aleniglipron in Nature Medicine, CagriSema REIMAGINE 2 14.2% T2D loss, survodutide SYNCHRONIZE-1, Hengrui HRS-7535, MetaVia, Lexicon.
Read digest →ADA's eve: Parabilis prices a $476M peptide IPO, plus pre-conference data from petrelintide, survodutide, Verdiva, and elecoglipron.
Read digest →